Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zenagamtide in ASCVD and Overweight/Obesity
NCT07861100Phase 3Not yet recruiting
- Sponsor
- Novo Nordisk
- Start
- Oct 2026
- Primary completion
- Sep 2030
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic cardiovascular disease (ASCVD) and obesity comparing Zenagamtide with Placebo (2 arms). Primary endpoint: 4-point composite major adverse cardiovascular events up to 203 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
amycretin
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)obesity
Beyond the preview
Go deeper on NCT07861100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07861100.